Pur­due sub­sidiary nabs non-opi­oid drug for pain; Or­biMed backs small biotech's 'su­pe­ri­or' drug

As Pur­due Phar­ma reach­es the fi­nal stages of a mas­sive bank­rupt­cy deal cen­tered around its re­spon­si­bil­i­ty in the opi­oid cri­sis, one of its sub­sidiaries is qui­et­ly build­ing a port­fo­lio of non-opi­oid treat­ments for pain.

Stam­ford, CT-based Im­bri­um has ex­er­cised its op­tion to li­cense what’s for­mer­ly known as ALV-107 from PureTech Health, whose af­fil­i­ate Aliv­io Ther­a­peu­tics had de­vised a way to bind se­lec­tive­ly to in­flamed tis­sue and achieve tar­get­ed im­munomod­u­la­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.